Literature DB >> 20180064

[Tumour recurrence].

O W Hakenberg1, F Sedlmayer.   

Abstract

In Chap. 6 the German S3 guideline on prostate cancer addresses the issue of tumour recurrence following primary local treatment with curative intent, i.e. after radical prostatectomy or a form of radiotherapy. PSA recurrence after radical surgery is defined as a rising PSA of 0.2 ng/ml and after radiotherapy as an increase of at least 2 ng/ml above the individual nadir. Factors for the clinical judgement that a local recurrence is likely are empirical indicators from the primary tumour diagnosis and the PSA course after primary treatment. Salvage external beam radiotherapy after radical surgery does not require the histological proof of a local recurrence and should be initiated early (PSA < 0.5 ng/ml). Before salvage radical prostatectomy, which carries a higher complication rate, the presence of a local recurrence should be histologically verified.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20180064     DOI: 10.1007/s00120-010-2239-2

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  33 in total

1.  Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?

Authors:  Pia Bader; Fiona C Burkhard; Regula Markwalder; Urs E Studer
Journal:  J Urol       Date:  2003-03       Impact factor: 7.450

2.  Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.

Authors:  Mark K Buyyounouski; Alexandra L Hanlon; Debra F Eisenberg; Eric M Horwitz; Steven J Feigenberg; Robert G Uzzo; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-19       Impact factor: 7.038

3.  [Radical salvage prostatectomy : Treatment of local recurrence of prostate cancer after radiotherapy].

Authors:  A Heidenreich; R Semrau; D Thüer; D Pfister
Journal:  Urologe A       Date:  2008-11       Impact factor: 0.639

4.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Journal:  JAMA       Date:  2005-07-27       Impact factor: 56.272

5.  Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate.

Authors:  C Catton; M Gospodarowicz; P Warde; T Panzarella; P Catton; M McLean; M Milosevic
Journal:  Radiother Oncol       Date:  2001-04       Impact factor: 6.280

6.  Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer.

Authors:  M M Morris; K C Dallow; A L Zietman; J Park; A Althausen; N M Heney; W U Shipley
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-07-01       Impact factor: 7.038

7.  Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen.

Authors:  Stephen J Freedland; Mark E Sutter; Frederick Dorey; William J Aronson
Journal:  Urology       Date:  2003-02       Impact factor: 2.649

8.  Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.

Authors:  Bruce J Trock; Misop Han; Stephen J Freedland; Elizabeth B Humphreys; Theodore L DeWeese; Alan W Partin; Patrick C Walsh
Journal:  JAMA       Date:  2008-06-18       Impact factor: 56.272

9.  Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy.

Authors:  Vincenzo Scattoni; Maria Picchio; Nazareno Suardi; Cristina Messa; Massimo Freschi; Marco Roscigno; Luigi Da Pozzo; Aldo Bocciardi; Patrizio Rigatti; Ferruccio Fazio
Journal:  Eur Urol       Date:  2007-03-20       Impact factor: 20.096

10.  PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer.

Authors:  Roman Ganzer; Sebastian Rogenhofer; Bernhard Walter; Jens-Claudio Lunz; Martin Schostak; Wolf F Wieland; Andreas Blana
Journal:  Eur Urol       Date:  2007-07-17       Impact factor: 20.096

View more
  1 in total

1.  [Prostate-specific antigen for treatment monitoring].

Authors:  M Graefen; M Fröhner; M Wirth
Journal:  Urologe A       Date:  2011-03       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.